Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer deaths in both men and women world-wide. Despite development of scientific, PC remains lethal disease. Recently, cancer stem cells (CSC) of pancreatic cancer that often are resistant to treatment have been identified. Present study aims to investigate the existence and prognostic value of CSC markers in PDAC patients.
52 hematoxylin and eosin-stained slides cut from formalin-fixed, paraffin-embedded (FFPE) PDAC tissues were evaluated by a pathologist, and the areas of the slide representing tumor and normal were identified. The samples were analyzed for the presence and differential expression of LGR5, CD44 and CD133 using RT2 Profiler PCR Array Data Analysis (http://www.sabiosciences.com/pcr/arrayanalysis.php) to compare the PCR array analysis results and the characteristics of the tumors and cases.
Of the 52 patients, 29 were men and 23 were women, with an average age of 63 years (range, 26-91 years). All patients underwent pancreaticoduodenectomy (Whipple prosedure). The median size of tumors was 2.3 cm (range, 0.5-6.0 cm). Lymphatic, vascular, and perineural invasions were observed in the tumors of 23 (44.2%), 9 (17.3%), and 5 (9.6%) patients, with 2 patients showing concurrent lymphatic, vascular, and perineural invasions. Tumors were classified as stage IA (n = 4), stage IB (n = 11), stage IIA (n = 7), stage IIB (n = 10), and stage III (n = 22). All surgically resected specimens showed negative (R0) resection margin status. The CD44 was not significantly expressed in eCC tumors compared to normal tissue. LGR5 and CD133 expression level was significantly higher in tumors than in corresponding normal tissues (4.5 fold, P = 0.034; 3.7 fold P = 0.045, respectively). Increased CD133 expression was associated with ampulla vateri tumor localization (P < 0.001). Over expression of LGR5 and CD133 were associated with short overall survival.
Here, we report that CD133 and LGR5 may acts as a functional CSC in the aggressivite of PDAC. Our results suggest that these molecules may serve as a candidate prognostic biomarker and target for new therapies in PDAC.
Clinical trial identification
Legal entity responsible for the study
Has not received any funding.
All authors have declared no conflicts of interest.